Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | CEL | P19835 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13898705 | 0.90 | HTR2C (0.48) | HTR2CHTR1AHTR7 | |
| SCHEMBL31240954 | 0.86 | HTR2C (0.52) | HTR2CPTGS2HTR1AHTR7CEL | |
| SCHEMBL1128139 | 0.80 | HTR2C (0.67) | HTR2CPTGS2HTR1AHTR7CEL | |
| SCHEMBL30603834 | 0.80 | HTR2C (0.67) | HTR2CPTGS2HTR1AHTR7CEL | |
| SCHEMBL22136718 | 0.80 | HTR2C (0.50) | HTR2C | |
| SCHEMBL2530746 | 0.79 | KDM1A (0.45) | HTR2CPTGS2PTGDR2 | |
| SCHEMBL30626968 | 0.79 | KDM1A (0.45) | HTR2CPTGS2PTGDR2 | |
| SCHEMBL6386133 | 0.78 | HTR2C (0.69) | HTR2CPTGS2HTR1AHTR7 | |
| SCHEMBL31192260 | 0.77 | HTR2C (0.40) | HTR2C | |
| SCHEMBL1483812 | 0.77 | CEL (0.41) | HTR2CPTGS2HTR1AHTR7CEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | HTR2C 2790/4885PTGS2 2321/4885HTR1A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.